First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

Chabala, Chishala; Jacobs, Tom G.; Moraleda, Cinta; Ndaferankhande, John M.; Mumbiro, Vivian; Passanduca, Alfeu; Namuziya, Natasha; Tagarro García, Alfredo; Aarnoutse, Rob E.; EMPIRICAL clinical trial group; Et al.

doi:10.1093/jpids/piad088

Inicio

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

Chabala, Chishala; Jacobs, Tom G.; Moraleda, Cinta; Ndaferankhande, John M.; Mumbiro, Vivian; Passanduca, Alfeu; Namuziya, Natasha; Tagarro García, Alfredo; Aarnoutse, Rob E.; EMPIRICAL clinical trial group; Et al.

Use este identificador para citar o enlazar este ítem: http://hdl.handle.net/11268/12395

Fecha: 2023-10-16

Materia UNESCO: Aparato respiratorio
Materia UNESCO: Enfermedad transmisible
Materia UNESCO: Pediatría

Tipo: article

Versión del editor: https://doi.org/10.1093/jpids/piad088

Exportar a:

Resumen:

Optimal antituberculosis therapy is essential for favorable clinical outcomes. Peak plasma concentrations of first-line antituberculosis drugs in infants with living HIV receiving WHO-recommended dosing were low compared with reference values for adults, supporting studies on increased doses of first-line TB drugs in infants.

Mostrar el registro completo del ítem